STOCK TITAN

CCLD Form 144 Notice — 11,960 CCLDO Pref Series B for Sale on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for CCLD Preferred Series B: The filing reports a proposed sale of 11,960 shares of CCLDO Preferred Series B with an aggregate market value of $252,000 on an approximate sale date of 09/29/2025 on NASDAQ. The broker listed is Chapin Davis Investments (address provided). The securities were acquired from CareCloud, Inc. as compensation: 5,480 shares on 02/19/2022 and 6,480 shares on 12/16/2024, matching the total to be sold. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

  • Complete disclosure of number of shares (11,960), aggregate market value ($252,000), approximate sale date (09/29/2025) and exchange (NASDAQ)
  • Acquisition history is provided showing the shares were received as compensation on 02/19/2022 (5,480) and 12/16/2024 (6,480), matching the total to be sold
  • No sales in past three months are reported, which clarifies recent trading activity

Negative

  • None.

Insights

TL;DR Proposed sale of 11,960 preferred shares totaling $252,000, acquired as compensation in 2022 and 2024.

The filing is a routine Rule 144 notice documenting an insider/affiliate sale process through a broker with full disclosure of acquisition dates and amounts. The total amount and acquisition history are clearly stated, and there are no reported sales in the prior three months. From an investor-disclosure perspective, the form provides the necessary elements to satisfy Rule 144 notice requirements but does not include the identity of the selling person in the visible fields.

TL;DR Transparent filing of compensatory-origin preferred shares being offered for sale; no adverse items disclosed.

The document documents compensation-issued preferred shares being offered for sale and includes the broker and aggregate value. It contains the required representation regarding material undisclosed information. The filing does not present material governance concerns on its face, but it also omits the explicit named seller field in the visible content, which is a disclosure gap in the provided text rather than necessarily in the form itself.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for CCLD report?

The form reports a proposed sale of 11,960 CCLDO Preferred Series B with an aggregate market value of $252,000, expected to be sold on 09/29/2025 on NASDAQ.

Who acquired the securities being sold under the CCLD Form 144 and when?

The shares were acquired from CareCloud, Inc. as compensation: 5,480 on 02/19/2022 and 6,480 on 12/16/2024.

Was a broker named in the CCLD Form 144 filing?

Yes. The broker listed is Chapin Davis Investments with an address in Baltimore, MD.

Does the filing report any sales in the past three months for the seller?

The filing states Nothing to Report for securities sold during the past three months.

Does the filer assert knowledge of undisclosed material information about the issuer?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.